Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 3/20 | 0.57 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9017588 | 1.00 | CTSB (0.57) | CTSBATMMEN1KMT2AKLK5 | |
| SCHEMBL9078755 | 1.00 | CTSB (0.57) | CTSBATMMEN1KMT2AKLK5 | |
| SCHEMBL8539393 | 0.90 | KLK5 (0.52) | CTSBATMMEN1KMT2AKLK5 | |
| SCHEMBL7289822 | 0.90 | ATM (0.52) | CTSBATMMEN1KMT2AKLK5 | |
| SCHEMBL390555 | 0.88 | ATM (0.62) | CTSBATMCTSSCTSKCTSL | |
| SCHEMBL7094 | 0.88 | ATM (0.62) | CTSBATMCTSSCTSKCTSL | |
| SCHEMBL1094506 | 0.88 | ATM (0.62) | CTSBATMCTSSCTSKCTSL | |
| SCHEMBL20204700 | 0.86 | CTSS (0.65) | CTSBATMCTSSCTSKCTSL | |
| SCHEMBL28269148 | 0.86 | CTSS (0.65) | CTSBATMCTSSCTSKCTSL | |
| SCHEMBL22962275 | 0.86 | CTSS (0.65) | CTSBATMCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124498-B2 | Compositions and methods for modulating protease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
| WO-2018097999-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124498-B2 | Compositions and methods for modulating protease activity | RNASE1, ADAM8, CTRL | CTSB 8/4885ATM 1991/4885MEN1 3690/4885 |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | RNASE1, ADAM8, CTRL | CTSB 8/4885ATM 1991/4885MEN1 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.